When sFRP-2 was immunosuppressed, an increase in OB matrix mineralisation was also seen, suggesting sFRP-2 as a potential target for MBD treatment [33], viz., that it is possible to block and reverse its effects. Here, SFRP2 is linked to Marchiafava-Bignami disease.